isabelobrien, Author at European Medical Journal - Page 37 of 66

MHRA signs off on Astellas' gastric cancer treatment

Astellas Pharma has received approval from the UK’s MHRA for its innovative therapy designed to treat gastric cancer.

FDA nod for world's first needle-free allergic reaction treatment

The FDA has granted approval for an innovative epinephrine nasal spray, making it the first needle-free emergency treatment for potentially fatal allergic reactions.

Upgrading the US congress customer experience

A US congress is the place to put your drug on the map, but is this landscape the home of great customer experience for HCPs?

Astellas’ Tadaaki Taniguchi on how to challenge the status quo

In this season finale of the podcast, Isabel speaks to Dr Tadaaki Taniguchi, Chief Medical Officer, Head of Medical and Development, Astellas Pharma.

AZ, GSK, Novartis, BMS and Sanofi lead Q2 2024 sales growth

The pharma industry shows strong growth into the second quarter of 2024, with companies reporting substantial YoY profit increases in Q2.

Elon Musk's Neuralink inserts brain implant into second patient

Elon Musk’s Neuralink has implanted its brain implant into a new patient, making them the second person to take part in the trial.

Taking control of customer experience

The team explores how the industry may be missing out on insights from HCPs and hears from Robert Tegge, Associate Principal, ZS, who shares valuable insights on congresses.

Spotlight: July 2024

Catch up on the top pharma news stories of July in EMJ GOLD’s monthly round-up, including insights on pharma’s use of social media.

Eli Lilly’s weight loss drug shows promise in heart failure

The weight loss drug reduces the risk of hospitalisation, death and more for adults with obesity and a common form of heart failure.

BMS boss reacts to soon-to-be-announced IRA prices

BMS has been a vocal opponent of drug price negotiations under the US’ Inflation Reduction Act, but a price preview may have allayed fears.